On August 1, 2023, biopharmaceutical company Forte Biosciences announced key R&D updates for its product candidate FB-102 (a proprietary molecule with potentially broad autoimmune applications including in such indications as graft versus host disease, vitiligo, and alopecia areata) as well as the closing of $25 million in financing to support the advancement of FB-102. Investors include Alger, BVF Partners, Farallon Capital Management, Perceptive Advisors, and Tybourne Capital Management.

Wilson Sonsini Goodrich & Rosati represented Forte Biosciences in the transaction. The Wilson Sonsini team was led by Dan Koeppen, Ben Capps, and Brandon Shaw.

For more information, please see Forte Biosciences' press release.